- Hepatitis B
- Vaccine Recommendations
Can you show the options of how to complete adult hepatitis B vaccination with different vaccine products?
In general, vaccination series should be completed with the same product. However, CDC guidance states that you may complete a hepatitis B vaccination series with any available, age-appropriate hepatitis B product if the brand of the previous dose is unknown or unavailable.
One hepatitis B vaccine (Heplisav-B, Dynavax) is recommended as a 2-dose series, with doses administered at least 4 weeks apart. All other hepatitis B vaccine product options for adults (Engerix-B, GSK; PreHevbrio, VBI; Recombivax HB, Merck; Twinrix [HepA-HepB], GSK) are routinely recommended on a 3-dose schedule: 0, 1-2 months, and 6 months; dose 2 may be given a minimum of 4 weeks after dose 1 and dose 3 may be given a minimum of 8 weeks after dose 2 and 16 weeks after dose 1. The table below does not address the accelerated, 4-dose Twinrix (combination HepA-HepB) schedule option (doses given on days 0, 7, 21, and 12 months), nor does it address completion of the hepatitis A component of Twinrix.
The table below displays the options and timing for hepatitis B vaccination with a mixed-product series. All mixed-product options require 3 doses because the only 2-dose option is two doses of Heplisav-B.
Timing of completion of a routine adult hepatitis B vaccination schedule with a single product or mixed product series:
Dose 1 | Dose 2 (at least 4 weeks after dose 1) |
Dose 3 (at least 8 weeks after dose 2 and 16 weeks after dose 1) |
|
Routine, single product schedule | H* | H | — |
E, P, R, or T* | Same product as dose 1 | Same product as dose 2 | |
If different products are used | E, P, R, or T | E, P, R, or T | E, P, R, or T |
H | E, P, R, or T | E, P, R, or T | |
E, P, R, or T | H | E, P, R, or T | |
E, P, R, or T | E, P, R, or T | H | |
H | E, P, R, or T | H | |
E, P, R, or T | H | H** |
* H = Heplisav-B; E = Engerix-B; P = PreHevbrio; R = Recombivax HB; T = Twinrix
** If two doses of H are used to complete a series started with E, P, R, or T, the final dose may be administered 4 weeks after dose 2 (for a complete H series). A 3-dose series containing 2 doses of H administered at least 4 weeks apart is valid, irrespective of the interval from doses of E, P, R, or T.